Vitrafy Life Sciences (ASX:VFY)
ASX announcement history & article coverage
Transparent by design.
Announcments by Vitrafy Life Sciences (ASX:VFY) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notification of cessation of securities - VFY
Application for quotation of securities - VFY
Change of Director's Interest Notice - Correction
Change of Director's Interest Notices
Application for quotation of securities - VFY
Expiry of Voluntary Escrow Restrictions
Results of Oversubscribed Share Purchase Plan
Vitrafy Share Purchase Plan Opens - SPP Offer Booklet
Vitrafy Life Sciences launches A$2 million Share Purchase Plan at A$2.60 per share
Cleansing Notice
Application for quotation of securities - VFY
Proposed issue of securities - VFY
Vitrafy Equity Raising Presentation
Vitrafy announces A$30m capital raising to expand cryopreservation platform and US operations
Vitrafy Placement Completion and SPP Announcement
Vitrafy Life Sciences raises A$30 million via institutional placement to fund US growth and manufacturing
Trading Halt
Vitrafy Investor Presentation
Vitrafy enters a partnership with Vitalant Innovation Center
Vitrafy partners with Vitalant to address red blood cell cryopreservation technology gap
Phase 2 USAISR Platelet Results Investor Briefing
Vitrafy Life Sciences to Present Phase II Platelet Study Results in Investor Webinar
Phase 2 USAISR Platelet Results Investor Presentation
Vitrafy achieves successful U.S. Army-validated Phase II platelet cryopreservation results, advancing FDA registration plans
Final US Army Phase 2 Platelet Results
Vitrafy completes successful US Army Phase II platelet cryopreservation study with superior no-wash protocol
Quarterly Investor Briefing Presentation
Q3 FY26 Quarterly Activities Report and Appendix 4C
Vitrafy completes Phase II military platelet study with strong results, advances FDA registration and commercial partnerships
Vitrafy Q3 FY26 Investor Briefing